-
Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
•
The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative drugs and medical devices included in the city’s list, with 24 products making the shortlist. This initiative is aimed at promoting local innovation and development within the pharmaceutical and medical device sectors. Among the notable…
-
Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment
•
BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has received fast-track designation from the US Food and Drug Administration (FDA) for the treatment of visible tophi in patients with gout. This Category 1 drug, co-developed with US firm Arthrosi Therapeutics Inc., is a next-generation…
-
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
•
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by ‘colluding with other…
-
Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study
•
China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II clinical study for its pipeline candidate drug AR882, co-developed with Arthrosi Therapeutics Inc., for the treatment of gout. The randomized, placebo-controlled global study involved 42 patients, and after 6 weeks of treatment, results indicated that…
